Proscar: Clinically Proven 5mg Finasteride for BPH Management
Proscar
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.32 | $79.00 (0%) | 🛒 Add to cart |
| 90 | $1.20 | $118.50 $108.00 (9%) | 🛒 Add to cart |
| 120 | $1.11 | $158.00 $133.00 (16%) | 🛒 Add to cart |
| 180 | $0.92 | $237.00 $166.00 (30%) | 🛒 Add to cart |
| 270 | $0.81 | $355.50 $220.00 (38%) | 🛒 Add to cart |
| 360 | $0.75
Best per pill | $474.00 $271.00 (43%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.83 | $55.00 (0%) | 🛒 Add to cart |
| 60 | $1.40 | $110.00 $84.00 (24%) | 🛒 Add to cart |
| 90 | $1.24 | $165.00 $112.00 (32%) | 🛒 Add to cart |
| 120 | $1.18 | $220.00 $141.00 (36%) | 🛒 Add to cart |
| 180 | $1.10 | $330.00 $198.00 (40%) | 🛒 Add to cart |
| 270 | $1.05 | $495.00 $283.00 (43%) | 🛒 Add to cart |
| 360 | $1.02
Best per pill | $660.00 $369.00 (44%) | 🛒 Add to cart |
Proscar (finasteride 5mg) is a prescription medication specifically formulated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men. As a 5-alpha-reductase inhibitor, it targets the hormonal pathway responsible for prostate growth, offering a non-surgical approach to managing urinary symptoms associated with an enlarged prostate. This oral therapy works by systematically reducing dihydrotestosterone (DHT) levels, leading to measurable decreases in prostate volume and subsequent improvement in urinary flow. Clinical studies demonstrate that consistent use can provide significant relief from obstructive and irritative voiding symptoms while potentially reducing the need for surgical intervention.
Features
- Contains 5mg finasteride as the active pharmaceutical ingredient
- Film-coated, pentagon-shaped tablets for easy identification
- Available in 30-count and 90-count blister packs
- Manufactured under strict pharmaceutical quality standards
- Requires prescription and medical supervision
- Stable shelf life of 24 months when stored properly
Benefits
- Reduces prostate size by approximately 20-25% after 6-12 months of treatment
- Improves urinary flow rate by 1.5-2.0 mL/sec on average
- Decreases risk of acute urinary retention and BPH-related surgery
- Provides relief from nocturia, urinary frequency, and urgency
- Addresses the underlying hormonal mechanism of prostate growth
- Offers convenient once-daily dosing regimen
Common use
Proscar is primarily indicated for the management of symptomatic benign prostatic hyperplasia in men with demonstrated prostate enlargement. It is prescribed for patients experiencing moderate to severe urinary symptoms including weak urinary stream, hesitancy, incomplete bladder emptying, increased frequency (especially nocturia), and urgency. Treatment is typically initiated when symptoms significantly impact quality of life or when objective measures (PSA levels, prostate volume, urinary flow rates) indicate progressive BPH. The medication is used as long-term therapy rather than for immediate symptom relief, with maximum benefits typically observed after 6-12 months of continuous treatment.
Dosage and direction
The recommended dosage is one 5mg tablet taken orally once daily, with or without food. Tablets should be swallowed whole with a glass of water and not crushed or broken. Administration at approximately the same time each day maintains consistent drug levels. Treatment response should be evaluated at 6-month intervals, with continuation of therapy based on symptomatic improvement and tolerability. For patients with hepatic impairment, no dosage adjustment is typically required, though careful monitoring is advised. Elderly patients generally require no specific dosage modifications.
Precautions
Before initiating Proscar therapy, a digital rectal examination (DRE) and appropriate diagnostic tests should be performed to rule out prostate cancer. Patients should be informed that PSA levels will decrease by approximately 50% during treatment, requiring adjustment of PSA values when monitoring for prostate cancer. Women who are or may become pregnant should not handle crushed or broken tablets due to risk of absorption through the skin and potential fetal harm. Regular monitoring of prostate-specific antigen (PSA) levels, prostate volume, and urinary symptoms is recommended throughout treatment. Patients should report any breast changes, lumps, pain, or nipple discharge promptly to their physician.
Contraindications
Proscar is contraindicated in women who are pregnant or may become pregnant due to potential risk of abnormalities in male fetal genital development. It is also contraindicated in patients with hypersensitivity to finasteride or any component of the formulation. Pediatric patients and patients with history of liver disease or abnormal liver function tests require careful evaluation before initiation. The medication is not indicated for use in women or children under any circumstances.
Possible side effects
The most common adverse reactions (≥1%) include: decreased libido (3.4%), erectile dysfunction (4.9%), ejaculation disorder (2.8%), and decreased ejaculate volume (2.2%). Less frequently reported effects include breast tenderness and enlargement (0.5%), rash, pruritus, urticaria, and swelling of the lips and face. These sexual side effects typically resolve after discontinuation of therapy, though in some cases may persist. Post-marketing reports have included testicular pain, hematospermia, male infertility, and depression. Laboratory abnormalities may include decreased prostate-specific antigen (PSA) levels.
Drug interaction
No clinically significant drug interactions have been identified with Proscar. However, theoretical interactions may occur with other 5-alpha-reductase inhibitors, though concomitant use is not recommended. The medication does not appear to affect the cytochrome P450 system significantly. Caution is advised when administering with potent CYP3A4 inhibitors, though no specific interactions have been documented. Patients taking anticoagulants or other medications affecting bleeding time should be monitored, though no direct interactions have been established.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistency in daily dosing is important for maintaining therapeutic effect, but occasional missed doses are unlikely to significantly affect long-term treatment outcomes.
Overdose
No specific antidote for finasteride overdose exists. Single doses up to 400mg and multiple doses up to 80mg/day for three months have been administered without significant adverse effects. In case of suspected overdose, symptomatic and supportive treatment should be initiated. Gastric lavage may be considered if ingestion was recent. Since finasteride is highly protein-bound, dialysis is unlikely to be beneficial. Medical attention should be sought for any suspected overdose, particularly in women of childbearing potential where exposure could occur.
Storage
Store at room temperature (15-30°C or 59-86°F) in the original container. Protect from light and moisture. Keep the container tightly closed and out of reach of children and pets. Do not store in bathroom areas where moisture levels may fluctuate. Properly discard any expired or unused medication through medication take-back programs or according to local regulations. Do not flush medications down the toilet or pour down drains unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Proscar is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the same benefits or side effects. Patients should consult with their physician for proper diagnosis, treatment recommendations, and monitoring. The manufacturer and distributors are not liable for any adverse effects resulting from the use or misuse of this information.
Reviews
Clinical studies involving over 4,000 patients demonstrated that Proscar 5mg daily for 12 months improved symptom scores by approximately 30% and increased peak urinary flow rate by 1.6 mL/sec compared to placebo. The PLESS study (4-year, double-blind, placebo-controlled) showed that finasteride 5mg reduced the risk of acute urinary retention by 57% and the need for BPH-related surgery by 55%. Long-term extension studies indicate maintained efficacy for up to 6 years of continuous treatment. Real-world evidence supports these findings, with urologists reporting satisfactory symptom control in approximately 70-80% of appropriately selected patients. Patient-reported outcomes indicate greatest satisfaction among those with moderate to severe symptoms at baseline who maintain treatment for at least 6 months.